Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia

CMH Kharian Medical College

Status: Enrolling

Conditions: Post Herpetic Neuralgia (PHN); Herpes Zoster (HZ)

Treatments: Drug: Lacosamide; Drug: Pregabalin

Study type: Interventional

Funder types: Other

Identifiers

NCT06969417

CKMC/IERB/AC-00225

Details and patient eligibility

About

Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and/or evoked. PHN is likely to interfere with sleep and daily activities.

Pregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain.

Although Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed cases of herpes zoster suffering from postherpetic neuralgia
• Ages: 18 to 50
• Both male and female

Exclusion criteria

• Lack of consent
• Patient already taking pain killers for post herpetic neuralgia
• Patients suffering from other systemic illness

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

Group A

Active Comparator group

Description:

Group A will receive Cap Pregabalin, the first intervention

Treatment:

Drug: Pregabalin

Group B

Experimental group

Description:

Group B will receive Tab Lacosamide

Treatment:

Drug: Lacosamide